The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
Open accessAbstract
Antiangiogenic therapy resistance occurs frequently in patients with metastatic renal cell carcinoma (RCC). The purpose of this study was to understand the mechanism of resistance to sunitinib, an antiangiogenic small molecule, and to exploit this mechanism therapeutically. We hypothesized that sunitinib-induced upregulation of the prometastatic MET and AXL receptors is associated with resistance to sunitinib and with more aggressive tumor behavior. In the present study, tissue microarrays containing sunitinib-treated and untreated RCC tissues were stained with MET and AXL antibodies. The low malignant RCC cell line 786-O was chronically treated with sunitinib and assayed for AXL, MET, epithelial–mesenchymal transition (EMT) protein expression and activation. Co-culture experiments were used to examine the effect of sunitinib pretreatment on endothelial cell growth. The effects of AXL and MET were evaluated in various cell-based models by short hairpin RNA or inhibition by cabozantinib, the multi-tyrosine kinases inhibitor that targets vascular endothelial growth factor receptor, MET and AXL. Xenograft mouse models tested the ability of cabozantinib to rescue sunitinib resistance. We demonstrated that increased AXL and MET expression was associated with inferior clinical outcome in patients. Chronic sunitinib treatment of RCC cell lines activated both AXL and MET, induced EMT-associated gene expression changes, including upregulation of Snail and β-catenin, and increased cell migration and invasion. Pretreatment with sunitinib enhanced angiogenesis in 786-0/human umbilical vein endothelial cell co-culture models. The suppression of AXL or MET expression and the inhibition of AXL and MET activation using cabozantinib both impaired chronic sunitinib treatment-induced prometastatic behavior in cell culture and rescued acquired resistance to sunitinib in xenograft models. In summary, chronic sunitinib treatment induces the activation of AXL and MET signaling and promotes prometastatic behavior and angiogenesis. The inhibition of AXL and MET activity may overcome resistance induced by prolonged sunitinib therapy in metastatic RCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Garofalo, M., Romano, G., Di Leva, G., Nuovo, G., Jeon, Y.-J., Ngankeu, A., Sun, J., Lovat, F., Alder, H., Condorelli, G., et al. (2012) · Nature Medicine · doi:10.1038/nm.2577 · Cited by 365
RetractedMet, metastasis, motility and more
Birchmeier, C., Birchmeier, W., Gherardi, E., & Vande Woude, G. F. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1261 · Cited by 2,602
Pàez-Ribes, M., Allen, E., Hudock, J., Takeda, T., Okuyama, H., Viñals, F., Inoue, M., Bergers, G., Hanahan, D., & Casanovas, O. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.027 · Cited by 2,339
Cancer Invasion and the Microenvironment: Plasticity and Reciprocity
Friedl, P., & Alexander, S. (2011) · Cell · doi:10.1016/j.cell.2011.11.016 · Cited by 1,940
Targeting MET in cancer: rationale and progress
Gherardi, E., Birchmeier, W., Birchmeier, C., & Woude, G. V. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3205 · Cited by 1,423
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhang, Z., Lee, J. C., Lin, L., Olivas, V., Au, V., LaFramboise, T., Abdel-Rahman, M., Wang, X., Levine, A. D., Rho, J. K., et al. (2012) · Nature Genetics · doi:10.1038/ng.2330 · Cited by 1,224
Intratumor microvessel density as a prognostic factor in cancer.
Weidner, N. (1995) · PubMed Central · Cited by 866
(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)00002-x · Cited by 751
Histopathology and Classification of Renal Cell Tumors (Adenomas, Oncocytomas and Carcinomas)
Thoenes, W., Störkel, S., & Rumpelt, H. J. (1986) · Pathology - Research and Practice · doi:10.1016/s0344-0338(86)80001-2 · Cited by 664
Smith, D. C., Smith, M. R., Sweeney, C., Elfiky, A. A., Logothetis, C., Corn, P. G., Vogelzang, N. J., Small, E. J., Harzstark, A. L., Gordon, M. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.0494 · Cited by 446
Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma
Huang, D., Ding, Y., Zhou, M., Rini, B. I., Petillo, D., Qian, C.-N., Kahnoski, R., Futreal, P. A., Furge, K. A., & Teh, B. T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3965 · Cited by 417
Sennino, B., Ishiguro-Oonuma, T., Wei, Y., Naylor, R. M., Williamson, C. W., Bhagwandin, V., Tabruyn, S. P., You, W.-K., Chapman, H. A., Christensen, J. G., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0240 · Cited by 408
MET: a promising anticancer therapeutic target
Peters, S., & Adjei, A. A. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.71 · Cited by 280
Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET
Rankin, E. B., Fuh, K. C., Castellini, L., Viswanathan, K., Finger, E. C., Diep, A. N., LaGory, E. L., Kariolis, M. S., Chan, A., Lindgren, D., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404848111 · Cited by 269
Self-citationYe, X., Li, Y., Stawicki, S., Couto, S., Eastham-Anderson, J., Kallop, D., Weimer, R., Wu, Y., & Pei, L. (2010) · Oncogene · doi:10.1038/onc.2010.268 · Cited by 232
AXL Is an Essential Factor and Therapeutic Target for Metastatic Ovarian Cancer
Rankin, E. B., Fuh, K. C., Taylor, T. E., Krieg, A. J., Musser, M., Yuan, J., Wei, K., Kuo, C. J., Longacre, T. A., & Giaccia, A. J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1267 · Cited by 229
Self-citationAxl is essential for VEGF‐A‐dependent activation of PI3K/Akt
Ruan, G., & Kazlauskas, A. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.21 · Cited by 223
Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors
Kumar, R., Crouthamel, M.-C., Rominger, D. H., Gontarek, R. R., Tummino, P. J., Levin, R. A., & King, A. G. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605366 · Cited by 218
Multiple Roles for the Receptor Tyrosine Kinase Axl in Tumor Formation
Holland, S. J., Powell, M. J., Franci, C., Chan, E. W., Friera, A. M., Atchison, R. E., McLaughlin, J., Swift, S. E., Pali, E. S., Yam, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0993 · Cited by 201
Jonasch, E., Wood, C. G., Matin, S. F., Tu, S.-M., Pagliaro, L. C., Corn, P. G., Aparicio, A., Tamboli, P., Millikan, R. E., Wang, X., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3660 · Cited by 188
Self-citationc-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma
Gibney, G. T., Aziz, S. A., Camp, R. L., Conrad, P., Schwartz, B. E., Chen, C. R., Kelly, W. K., & Kluger, H. M. (2013) · Annals of Oncology · doi:10.1093/annonc/mds463 · Cited by 177
Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors
Linger, R. M., Keating, A. K., Earp, H. S., & Graham, D. K. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2010.515980 · Cited by 168
A phase I study of cabozantinib (XL184) in patients with renal cell cancer
Choueiri, T. K., Pal, S. K., McDermott, D. F., Morrissey, S., Ferguson, K. C., Holland, J., Kaelin, W. G., & Dutcher, J. P. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu184 · Cited by 163
Rahimi, N., Hung, W., Tremblay, E., Saulnier, R., & Elliott, B. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.50.33714 · Cited by 160
Griffioen, A. W., Mans, L. A., de Graaf, A. M. A., Nowak-Sliwinska, P. M., de Hoog, C. L. M. M., de Jong, T. A. M., Vyth‐Dreese, F. A., B, J. R. V. B., Bex, A., & Jonasch, E. W. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0002 · Cited by 155
Self-citationGustafsson, A., Martuszewska, D., Johansson, M., Ekman, C., Hafizi, S., Ljungberg, B., & Dahlbäck, B. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2514 · Cited by 152
Bentzien, F., Zuzow, M., Heald, N., Gibson, A., Shi, Y., Goon, L. H., Yu, P., Engst, S., Zhang, W., Huang, D., et al. (2013) · Thyroid · doi:10.1089/thy.2013.0137 · Cited by 137
Jonasch, E. W., Corn, P. G., Pagliaro, L. C., Warneke, C. L., Johnson, M. M., Tamboli, P., Ng, C. S., Aparicio, A. M., Ashe, R. G., Wright, J. J., et al. (2009) · Cancer · doi:10.1002/cncr.24685 · Cited by 128
Self-citationHo, M.-Y., Tang, S., Chuang, M., Cha, T., Li, J.-Y., Sun, G.-H., & Sun, K. (2012) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-12-0160 · Cited by 125
Leconet, W., Larbouret, C., Chardès, T., Thomas, G., Neiveyans, M., Busson, M., Jarlier, M., Radosevic‐Robin, N., Pugnière, M., Bernex, F., et al. (2013) · Oncogene · doi:10.1038/onc.2013.487 · Cited by 116
Zhang, Y., Guessous, F., Kofman, A., Schiff, D., & Abounader, R. (2010) · PubMed · Cited by 88
Expression of the Proto-Oncogene Axl in Renal Cell Carcinoma
Chung, B. I., Malkowicz, S. B., Nguyen, T. B., Libertino, J. A., & McGarvey, T. W. (2003) · DNA and Cell Biology · doi:10.1089/10445490360708946 · Cited by 82
Chinchar, E., Makey, K. L., Gibson, J., Chen, F., Cole, S. A., MEGASON, G. C., Vijayakumar, S., Miele, L., & Gu, J. (2014) · Vascular Cell · doi:10.1186/2045-824x-6-12 · Cited by 82
Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays
Gujral, T. S., Karp, R. L., Finski, A., Chan, M. M., Schwartz, P. E., MacBeath, G., & Sorger, P. K. (2012) · Oncogene · doi:10.1038/onc.2012.378 · Cited by 72
Cytoplasmic Sequestration of p27 via AKT Phosphorylation in Renal Cell Carcinoma
Kim, J., Jonasch, E., Alexander, A., Short, J. D., Cai, S., Wen, S., Tsavachidou, D., Tamboli, P., Czerniak, B. A., Do, K., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0170 · Cited by 67
Self-citationCytoplasmic ACK1 Interaction with Multiple Receptor Tyrosine Kinases Is Mediated by Grb2
Lin, P.-C., Chan, P. M., Chan, W., & Manser, E. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.072660 · Cited by 58
Targeting the Hepatocyte Growth Factor/c-Met Signaling Pathway in Renal Cell Carcinoma
Harshman, L. C., & Choueiri, T. K. (2013) · The Cancer Journal · doi:10.1097/ppo.0b013e31829e3c9a · Cited by 56
Tsavachidou-Fenner, D., Tannir, N. M., Tamboli, P., Liu, W., Petillo, D., Teh, B. T., Mills, G. B., & Jonasch, E. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp600 · Cited by 53
Self-citationGas6 and the Receptor Tyrosine Kinase Axl in Clear Cell Renal Cell Carcinoma
Gustafsson, A., Boström, A.-K., Ljungberg, B., Axelson, H., & Dahlbäck, B. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007575 · Cited by 48
Targeted therapy for renal cell carcinoma: The next lap
Tan, M.-H., & Kanesvaran, R. (2014) · Journal of Carcinogenesis · doi:10.4103/1477-3163.127638 · Cited by 30
Plimack, E. R., Tannir, N. M., Lin, E., Bekele, B. N., & Jonasch, E. W. (2009) · Cancer · doi:10.1002/cncr.24211 · Cited by 29
Self-citationSinghal, E., & Sen, P. (2011) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2011.04.006 · Cited by 26
Ellison, A. R., Lofing, J., & Bitter, G. A. (2003) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(03)00257-7 · Cited by 8
Cited by
Hsieh, J. J., Purdue, M. P., Signoretti, S., Swanton, C., Albiges, L., Schmidinger, M., Heng, D. Y., Larkin, J., & Ficarra, V. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.9 · Cited by 2,426
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Abou-Alfa, G. K., Meyer, T., Cheng, A.-L., El-Khoueiry, A. B., Rimassa, L., Ryoo, B.-Y., Cicin, I., Merle, P., Chen, Y., Park, J.-W., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1717002 · Cited by 2,344
Systemic Therapy for Metastatic Renal-Cell Carcinoma
Choueiri, T. K., & Motzer, R. J. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1601333 · Cited by 1,284
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
Choueiri, T. K., Escudier, B., Powles, T., Mainwaring, P. N., Rini, B. I., Donskov, F., Hammers, H., Hutson, T. E., Lee, J.-L., Peltola, K., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510016 · Cited by 1,239
Self-citationChoueiri, T. K., Escudier, B., Powles, T., Tannir, N. M., Mainwaring, P. N., Rini, B. I., Hammers, H. J., Donskov, F., Roth, B. J., Peltola, K., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30107-3 · Cited by 958
Self-citation
Metadata
- Authors
- Zhou, L., Liu, X.-D., Sun, M., Zhang, X., German, P., Bai, S., Ding, Z., Tannir, N., Wood, C. G., Matin, S. F., Karam, J. A., Tamboli, P., Sircar, K., Rao, P., Rankin, E. B., Laird, D. A., Hoang, A. G., Walker, C. L., Giaccia, A. J., & Jonasch, E.
- Venue
- Oncogene
- Published
- 2015-09-14
- Volume
- 35
- Issue
- 21
- Pages
- 2687-2697
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W1612634664
- Cited by
- 395
- References
- 43
- FWCI
- 29.97
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.